In the early innings of 2024, there was a flurry of consolidation in the biotech industry. It stoked hopes that this would finally be the year in which well-heeled blue-chip pharmaceutical companies would spend some of their cash on faster-growing biotech firms. That mergers and acquisitions activity has waned in recent months, but there’s still [...] The post Big Pharma Has the Firepower for Biotech Deal-Making appeared first on ETF Trends .